COLGATE PALMOLIVE CO (CL) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-13

Key Insights

All 10 director nominees were successfully elected with strong support, with Christopher S. Boerner receiving the highest approval at 99.1% of votes cast, indicating solid shareholder confidence in board composition and governance.
PricewaterhouseCoopers LLP was ratified as the independent auditor with 92.3% shareholder approval, demonstrating continued confidence in the company's financial oversight and audit practices.
Executive compensation received advisory approval with 93.2% support, suggesting shareholders are aligned with management's pay structure and incentive arrangements.
Two activist-backed stockholder proposals were decisively rejected: the DEI-related proposal received only 2.2% support and the independent board chairman proposal received only 28.8% support, indicating the current board structure and leadership approach have strong shareholder backing.

Want the newest filings?

This analysis covers the filing from 2026-05-13. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-05-01

Colgate-Palmolive expanded its Strategic Growth and Productivity Program with cumulative pre-tax charges now estimated at $350-550 million (up from $200-300 million), indicating significant restructuring scope but also confidence in long-term strategic positioning aligned with 2030 goals.
The program's cost structure shows 70-80% employee-related expenses with 80-90% resulting in cash expenditures, representing substantial near-term cash outflows primarily through 2028, though the company appears to anticipate efficiency gains that justify the investment.
Geographic allocation reveals the heaviest restructuring burden on EMEA (25-30%) and Corporate (20-25%), suggesting operational consolidation in overhead-heavy regions, while Asia Pacific receives lighter adjustment (10-15%), potentially reflecting stronger growth markets.
Q1 2026 earnings were announced alongside this expansion, but the filing provides no earnings surprises or financial performance details, limiting visibility on whether operational results justify the increased restructuring commitment.

Filed: 2026-04-09

Colgate-Palmolive has announced the retirement of its Chief Legal Officer and Secretary, Jennifer M. Daniels, and the appointment of Betsy Fishbone as the new Chief Legal Officer and Secretary effective June 1, 2026, indicating a transition in the company's leadership.
The company has also elected Jennifer M. Daniels to the position of Vice Chair, which suggests a planned transition and continuity in the company's operations.
The 8-K filing does not mention any material agreements, earnings surprises, or other significant events, indicating this is a routine organizational change.

Filed: 2026-03-17

Colgate-Palmolive has realigned its reportable operating segments by combining its Europe and Africa/Eurasia (excluding Russia and Belarus) segments, as well as its Skin Health business, into a new Europe, Middle East and Africa segment. This change is part of the company's Strategic Growth and Productivity Program to optimize operations and drive growth.
Russia and Belarus, previously reported in the Africa/Eurasia segment, will now be part of the Asia Pacific segment. This realignment does not impact the company's historical consolidated results, financial position, or cash flows.
To provide investors with historical information on the new reporting structure, Colgate-Palmolive has recasted its segment information for the past three years and included it as an exhibit to the 8-K filing.

Filed: 2026-03-12

Colgate-Palmolive appointed Christopher S. Boerner, Ph.D., the CEO and Board Chair of Bristol-Myers Squibb, to its Board of Directors, adding significant pharmaceutical and healthcare expertise to the company's leadership.
Steven A. Cahillane, a current Colgate-Palmolive director, announced he will not stand for re-election to the Board due to the demands of his new role as CEO of The Kraft Heinz Company.
Colgate-Palmolive is diversifying its Board composition by bringing in an experienced executive from the pharmaceutical industry, which could help the company explore new growth opportunities in adjacent markets.

Other reports for COLGATE PALMOLIVE CO

Insider Trading Quarterly Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.